drugset / Trial / NCT01210885

Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents

NCT01210885

Phase 2 Completed 495 enrolled Novartis Vaccines
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this phase 2 study is to evaluate the safety, tolerability and immunogenicity of two doses of 4 different investigational MenABCWY combination vaccine when administered to healthy adolescents aged 11-18 years.

Timeline

Start
2010-12
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Meningococcal Vaccine Vaccine Intramuscular